Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acrivon Therapeutics, Inc. Common Stock (ACRV)
USD1.91
-0.22 (-10.33%)
US NASDAQ Healthcare Biotechnology
Address
480 Arsenal Way 2472
Watertown, MA, US
Watertown, MA, US
CEO
Peter Blume-Jensen
Website
acrivon.com
IPO
2022-11-15
CIK 1781174 ISIN US0048901096
Description
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.91
-0.22 (-10.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
571.0K
Beta
1.91
Float Shares
22.21M
Free Float %
70.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.05% | -7.35% | +17.39% | +15.95% | -8.70% | -21.58% | +67.26% | -86.59% | -88.64% | -88.64% | -88.64% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
1.91
Low
17.00
+790.1%
Consensus
21.83
+1,042.9%
Median
20.00
+947.1%
High
30.00
+1,470.7%
DCF (Unlevered)
0.96
-50.0%
DCF (Levered)
1.01
-47.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 11 |
22.73
+1,090.1%
|
Quality scores
Altman Z-Score
-2.08
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+3.8% Q1'26: +3.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.6% ★ Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 6 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 145.5K (-100.0%)
|
1.50M
1.50M – 1.50M
+931.3% YoY
|
3.80M
3.80M – 3.80M
+153.1% YoY
|
21.38M
21.38M – 21.38M
+462.7% YoY
|
70.65M
70.65M – 70.65M
+230.5% YoY
|
144.13M
144.13M – 144.13M
+104.0% YoY
|
| EBITDA |
-79.55M
|
-82.76M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-80.56M
|
-84.11M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-80.56M
est: -97.85M (+17.7%)
|
-77.91M
est: -77.91M (+0.0%)
|
-86.77M
-99.77M – -71.26M
-11.4% YoY
|
-71.26M
-94.63M – -47.88M
+17.9% YoY
|
-145.20M
-163.53M – -27.25M
-103.8% YoY
|
-67.34M
-67.34M – -67.34M
+53.6% YoY
|
-37.54M
-37.54M – -37.54M
+44.2% YoY
|
| SGA |
25.21M
|
24.12M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.10
est: -2.51 (+16.5%)
|
-2.02
est: -2.03 (+0.3%)
|
-2.18
-2.59 – -1.85
-7.5% YoY
|
-1.95
-2.46 – -1.24
+10.5% YoY
|
-2.12
-4.25 – -0.71
-8.7% YoY
|
-1.75
-1.75 – -1.75
+17.5% YoY
|
-0.97
-0.97 – -0.97
+44.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
16
Total invested
4.48M
Insider transactions (90d)
2
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace North America L.P. | 1.22M | 5.90% | — | 1.22M | — | — | IA, PN | Delaware | 2023-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
16
-32 vs prev Q
New positions
7
Closed positions
39
Increased
8
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 8.34M +— (+0.0%) | 20.10M +5.0M (+33.1%) | 21.63% -0.056 pp | 0.21% +0.020 pp | USD9.12 -73.6% | 13 qtrs — |
| 2 | SANDS CAPITAL VENTURES, LLC | 2.12M +— (+0.0%) | 5.12M +1.3M (+33.1%) | 5.50% -0.014 pp | 0.99% +0.145 pp | USD10.27 -76.5% | 13 qtrs — |
| 3 | CITADEL ADVISORS LLC | 1.64M +100.6K (+6.5%) | 3.96M +1.2M (+41.8%) | 4.26% +0.251 pp | 0.00% +0.000 pp | USD9.78 -75.4% | 13 qtrs — |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 888.1K +— (+0.0%) | 2.14M +532.9K (+33.1%) | 2.30% -0.006 pp | 0.00% +0.000 pp | USD11.52 -79.1% | 13 qtrs — |
| 5 | VANGUARD GROUP INC | 698.9K +72.7K (+11.6%) | 1.68M +550.9K (+48.6%) | 1.81% +0.184 pp | 0.00% +0.000 pp | USD8.56 -71.8% | 12 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 634.2K +10.8K (+1.7%) | 1.53M +400.0K (+35.4%) | 1.64% +0.024 pp | 0.00% +0.001 pp | USD1.79 +34.6% | 8 qtrs — |
| 7 | TWO SIGMA INVESTMENTS, LP | 585.1K +265.9K (+83.3%) | 1.41M +832.3K (+144.0%) | 1.52% +0.687 pp | 0.00% +0.001 pp | USD1.89 +27.5% | 3 qtrs — |
| 8 | ACADIAN ASSET MANAGEMENT LLC | 581.2K +489.2K (+531.7%) | 1.40M +1.2M (+748.5%) | 1.51% +1.268 pp | 0.00% +0.002 pp | USD2.32 +3.9% | 2 qtrs — |
| 9 | MARSHALL WACE, LLP | 496.1K +346.4K (+231.4%) | 1.20M +924.6K (+341.2%) | 1.29% +0.897 pp | 0.00% +0.001 pp | USD4.53 -46.8% | 13 qtrs — |
| 10 | ACORN CAPITAL ADVISORS, LLC | 405.2K +— (+0.0%) | 976.6K +243.1K (+33.1%) | 1.05% -0.003 pp | 0.33% -0.041 pp | USD6.02 -60.0% | 5 qtrs — |
| 11 | UBS GROUP AG | 348.5K -334.7K (-49.0%) | 840.0K -396.6K (-32.1%) | 0.90% -0.873 pp | 0.00% 0.000 pp | USD1.81 +33.1% | 13 qtrs — |
| 12 | JANE STREET GROUP, LLC | 342.1K +52.8K (+18.3%) | 824.4K +300.9K (+57.5%) | 0.89% +0.135 pp | 0.00% +0.000 pp | USD1.38 +74.6% | 3 qtrs — |
| 13 | TWO SIGMA ADVISERS, LP | 333.8K +197.3K (+144.5%) | 804.4K +557.3K (+225.6%) | 0.87% +0.511 pp | 0.00% +0.001 pp | USD2.10 +14.8% | 3 qtrs — |
| 14 | BLACKROCK, INC. | 205.1K -125.8K (-38.0%) | 494.3K -104.7K (-17.5%) | 0.53% -0.329 pp | 0.00% +0.000 pp | USD6.84 -64.8% | 6 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 198.2K +6.2K (+3.2%) | 477.9K +130.2K (+37.4%) | 0.51% +0.015 pp | 0.00% +0.000 pp | USD8.67 -72.2% | 12 qtrs — |
| 16 | MILLENNIUM MANAGEMENT LLC | 121.5K -63.7K (-34.4%) | 292.9K -42.4K (-12.6%) | 0.32% -0.167 pp | 0.00% +0.000 pp | USD1.19 +102.5% | 3 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 119.4K +99.7K (+504.9%) | 287.8K +252.1K (+705.4%) | 0.31% +0.258 pp | 0.00% +0.000 pp | USD2.58 -6.6% | 7 qtrs — |
| 18 | STATE STREET CORP | 67.1K +— (+0.0%) | 161.8K +40.3K (+33.1%) | 0.17% 0.000 pp | 0.00% +0.000 pp | USD9.89 -75.6% | 12 qtrs — |
| 19 | NORTHERN TRUST CORP | 63.7K +21.6K (+51.1%) | 153.6K +77.2K (+101.2%) | 0.17% +0.056 pp | 0.00% +0.000 pp | USD7.39 -67.4% | 12 qtrs — |
| 20 | PRELUDE CAPITAL MANAGEMENT, LLC | 48.0K +48.0K (+100.0%) | 115.7K +115.7K (+100.0%) | 0.12% +0.125 pp | 0.01% +0.009 pp | USD2.41 +0.0% | 1 qtrs NEW |
| 21 | MORGAN STANLEY | 46.8K -10.3K (-18.1%) | 112.9K +9.4K (+9.1%) | 0.12% -0.027 pp | 0.00% +0.000 pp | USD4.24 -43.2% | 13 qtrs — |
| 22 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 42.9K +20.0K (+87.3%) | 103.4K +61.9K (+149.4%) | 0.11% +0.052 pp | 0.00% +0.001 pp | USD4.35 -44.6% | 9 qtrs — |
| 23 | SQUAREPOINT OPS LLC | 26.2K -78.2K (-74.9%) | 63.1K -125.8K (-66.6%) | 0.07% -0.203 pp | 0.00% 0.000 pp | USD1.19 +102.5% | 3 qtrs — |
| 24 | BARCLAYS PLC | 24.4K -8.9K (-26.7%) | 58.8K -174.3K (-74.8%) | 0.06% -0.023 pp | 0.00% +0.000 pp | USD5.76 -58.2% | 13 qtrs — |
| 25 | BAKER BROS. ADVISORS LP | 22.8K +— (+0.0%) | 55.0K +13.7K (+33.2%) | 0.06% 0.000 pp | 0.00% +0.000 pp | USD7.25 -66.8% | 8 qtrs — |
| 26 | QUADRATURE CAPITAL LTD | 20.7K +20.7K (+100.0%) | 50.0K +50.0K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.001 pp | USD2.41 +0.0% | 3 qtrs — |
| 27 | XTX TOPCO LTD | 20.6K -15.4K (-42.8%) | 49.6K -15.5K (-23.8%) | 0.05% -0.040 pp | 0.00% -0.002 pp | USD1.19 +102.5% | 3 qtrs — |
| 28 | DIMENSIONAL FUND ADVISORS LP | 18.4K -1.2K (-6.2%) | 44.3K +8.9K (+25.0%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD5.80 -58.4% | 7 qtrs — |
| 29 | VERMILLION & WHITE WEALTH MANAGEMENT GROUP, LLC | 18.1K +18.1K (+100.0%) | 43.6K +43.6K (+100.0%) | 0.05% +0.047 pp | 0.02% +0.024 pp | USD2.41 +0.0% | 1 qtrs NEW |
| 30 | BANK OF AMERICA CORP /DE/ | 17.4K -1.5K (-7.7%) | 42.0K +7.8K (+22.9%) | 0.05% -0.004 pp | 0.00% +0.000 pp | USD7.07 -65.9% | 12 qtrs — |
| 31 | JPMORGAN CHASE & CO | 16.9K +15.1K (+868.6%) | 40.6K +37.5K (+1,189.8%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD2.81 -14.2% | 12 qtrs — |
| 32 | SCHONFELD STRATEGIC ADVISORS LLC | 16.4K +16.4K (+100.0%) | 39.6K +39.6K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD2.41 +0.0% | 1 qtrs NEW |
| 33 | CITIGROUP INC | 14.6K -1.7K (-10.5%) | 35.2K +5.7K (+19.2%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD3.09 -22.0% | 12 qtrs — |
| 34 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12.4K +12.4K (+100.0%) | 30.0K +30.0K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD2.41 +0.0% | 4 qtrs — |
| 35 | POINT72 ASSET MANAGEMENT, L.P. | 10.9K +10.9K (+100.0%) | 26.2K +26.2K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD2.41 +0.0% | 1 qtrs NEW |
| 36 | AAF WEALTH MANAGEMENT, LLC | 10.7K +— (+0.0%) | 25.7K +6.4K (+33.1%) | 0.03% 0.000 pp | 0.01% +0.002 pp | USD1.81 +33.1% | 11 qtrs — |
| 37 | MAREX GROUP PLC | 10.0K +10.0K (+100.0%) | 24.1K +24.1K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD2.41 +0.0% | 1 qtrs NEW |
| 38 | FMR LLC | 8.6K +— (+0.0%) | 20.8K +5.2K (+33.1%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD2.73 -11.7% | 12 qtrs — |
| 39 | FEDERATED HERMES, INC. | 5.6K +3.2K (+131.3%) | 13.5K +9.1K (+208.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD1.89 +27.5% | 3 qtrs — |
| 40 | ROYAL BANK OF CANADA | 1.7K +763.0 (+80.5%) | 4.0K +2.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD2.08 +15.9% | 12 qtrs — |
| 41 | BNP PARIBAS ARBITRAGE, SNC | 634.00 -555.0 (-46.7%) | 1.5K -624.0 (-29.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD5.32 -54.7% | 5 qtrs — |
| 42 | NISA INVESTMENT ADVISORS, LLC | 584.00 +— (+0.0%) | 1.4K +350.0 (+33.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.45 -1.6% | 5 qtrs — |
| 43 | REDWOOD PARK ADVISORS LLC | 500.00 +— (+0.0%) | 1.2K +300.0 (+33.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.02 -60.0% | 5 qtrs — |
| 44 | RUSSELL INVESTMENTS GROUP, LTD. | 481.00 +— (+0.0%) | 1.2K +288.0 (+33.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.19 +102.5% | 8 qtrs — |
| 45 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 400.00 +— (+0.0%) | 964.00 +240.0 (+33.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.86 -58.9% | 7 qtrs — |
| 46 | EVERSOURCE WEALTH ADVISORS, LLC | 373.00 +— (+0.0%) | 899.00 +224.0 (+33.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.81 +33.1% | 2 qtrs — |
| 47 | OPTIMA CAPITAL LLC | 278.00 +278.0 (+100.0%) | 670.00 +670.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.41 +0.0% | 1 qtrs NEW |
| 48 | SBI SECURITIES CO., LTD. | 74.00 +— (+0.0%) | 178.00 +44.0 (+32.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.01 -59.9% | 5 qtrs — |
| 49 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | — -5.5K (-100.0%) | — -10.0K (-100.0%) | 0.00% -0.014 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 50 | TOWER RESEARCH CAPITAL LLC (TRC) | — -8.7K (-100.0%) | — -15.8K (-100.0%) | 0.00% -0.023 pp | 0.00% 0.000 pp | USD— | 13 qtrs SOLD |
| 51 | GF FUND MANAGEMENT CO. LTD. | — -650.0 (-100.0%) | — -1.2K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 52 | ALGERT GLOBAL LLC | — -44.6K (-100.0%) | — -81.0K (-100.0%) | 0.00% -0.116 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 53 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | — -1.2K (-100.0%) | — -2.2K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 54 | COLONY GROUP, LLC | — -19.8K (-100.0%) | — -987.9K (-100.0%) | 0.00% -0.052 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 144.8K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 345.1K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.8K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 5.1K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 375.17 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 868.0K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.9K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.0K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 418.33 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 46.12 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
1
Sells
1
Shares acquired
3.89M
Shares disposed
558.00
Cash buys
—
Cash sales
—
Net activity
+3,888,330
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Common Stock | 3,888,888 | 1.80 | 7.00M | 11,803,094 | I | ↗ |
| 2026-04-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 558 | 1.78 | 993.24 | 33,121 | D | ↗ |
| 2026-03-01 | Peterson Katharine | Officer | A-Award | A | Stock Option (Right to Buy) | 31,900 | 1.51 | 48.2K | 31,900 | D | ↗ |
| 2026-03-01 | Mirza Mansoor Raza | Officer | A-Award | A | Stock Option (Right to Buy) | 174,068 | 1.51 | 262.8K | 174,068 | D | ↗ |
| 2026-03-01 | Miller Mary | Officer | A-Award | A | Stock Option (Right to Buy) | 129,760 | 1.51 | 195.9K | 129,760 | D | ↗ |
| 2026-03-01 | Levy Adam D. | Officer | A-Award | A | Stock Option (Right to Buy) | 132,925 | 1.51 | 200.7K | 132,925 | D | ↗ |
| 2026-03-01 | Gamelin Erick | Officer | A-Award | A | Stock Option (Right to Buy) | 94,946 | 1.51 | 143.4K | 94,946 | D | ↗ |
| 2026-03-01 | Devroe Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 186,728 | 1.51 | 282.0K | 186,728 | D | ↗ |
| 2026-03-01 | Blume-Jensen Peter | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 417,210 | 1.51 | 630.0K | 417,210 | D | ↗ |
| 2026-02-21 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 14,265 | 1.53 | 21.8K | 2,080,204 | D | ↗ |
| 2026-02-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 116 | 1.63 | 189.08 | 4,006 | D | ↗ |
| 2026-02-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 217 | 1.63 | 353.71 | 33,679 | D | ↗ |
| 2026-02-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 471 | 1.63 | 767.73 | 14,812 | D | ↗ |
| 2026-02-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 723 | 1.63 | 1.2K | 74,585 | D | ↗ |
| 2026-02-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 1,302 | 1.63 | 2.1K | 2,094,469 | D | ↗ |
| 2026-01-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 659 | 1.98 | 1.3K | 33,896 | D | ↗ |
| 2026-01-14 | Levy Adam D. | Officer | P-Purchase | A | Common Stock | 8,832 | 1.70 | 15.0K | 20,983 | D | ↗ |
| 2026-01-14 | Blume-Jensen Peter | Director / Officer | P-Purchase | A | Common Stock | 49,000 | 1.68 | 82.1K | 2,095,771 | D | ↗ |
| 2026-01-13 | Devroe Eric | Officer | P-Purchase | A | Common Stock | 10,000 | 1.72 | 17.2K | 75,308 | D | ↗ |
| 2025-11-21 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 19,904 | 2.30 | 45.8K | 2,046,771 | D | ↗ |
| 2025-11-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 99 | 2.24 | 221.76 | 4,122 | D | ↗ |
| 2025-11-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 184 | 2.24 | 412.16 | 34,555 | D | ↗ |
| 2025-11-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 403 | 2.24 | 902.72 | 15,283 | D | ↗ |
| 2025-11-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 613 | 2.24 | 1.4K | 65,308 | D | ↗ |
| 2025-11-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 59,765 | 2.24 | 133.9K | 2,066,675 | D | ↗ |
| 2025-10-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 558 | 1.81 | 1.0K | 34,739 | D | ↗ |
| 2025-10-01 | Mirza Mansoor Raza | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 1.81 | 407.3K | 225,000 | D | ↗ |
| 2025-10-01 | Miller Mary | Officer | F-InKind | D | Common Stock | 284 | 1.81 | 514.04 | 35,297 | D | ↗ |
| 2025-08-21 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 19,905 | 1.32 | 26.3K | 2,126,440 | D | ↗ |
| 2025-08-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 99 | 1.39 | 137.61 | 4,221 | D | ↗ |
| 2025-08-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 184 | 1.39 | 255.76 | 35,581 | D | ↗ |
| 2025-08-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 403 | 1.39 | 560.17 | 15,686 | D | ↗ |
| 2025-08-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 613 | 1.39 | 852.07 | 65,921 | D | ↗ |
| 2025-08-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 59,766 | 1.39 | 83.1K | 2,146,345 | D | ↗ |
| 2025-08-01 | Levy Adam D. | Officer | F-InKind | D | Common Stock | 1,164 | 1.26 | 1.5K | 12,151 | D | ↗ |
| 2025-07-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 558 | 1.32 | 736.56 | 35,765 | D | ↗ |
| 2025-06-13 | TOMSICEK MICHAEL JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 1.20 | 24.3K | 20,275 | D | ↗ |
| 2025-06-13 | Shacham Sharon | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 1.20 | 24.3K | 20,275 | D | ↗ |
| 2025-06-13 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 20,275 | 1.20 | 24.3K | 20,275 | I | ↗ |
| 2025-06-13 | Palani Santhosh | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 1.20 | 24.3K | 20,275 | D | ↗ |
| 2025-06-13 | Magovcevic-Liebisch Ivana | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 1.20 | 24.3K | 20,275 | D | ↗ |
| 2025-06-13 | DiRocco Derek | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 1.20 | 24.3K | 20,275 | D | ↗ |
| 2025-06-13 | BAUM CHARLES M | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 1.20 | 24.3K | 20,275 | D | ↗ |
| 2025-05-21 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 19,904 | 1.15 | 22.9K | 2,206,111 | D | ↗ |
| 2025-05-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 99 | 1.14 | 112.86 | 4,320 | D | ↗ |
| 2025-05-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 184 | 1.14 | 209.76 | 36,323 | D | ↗ |
| 2025-05-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 403 | 1.14 | 459.42 | 16,089 | D | ↗ |
| 2025-05-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 613 | 1.14 | 698.82 | 66,534 | D | ↗ |
| 2025-05-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 59,766 | 1.14 | 68.1K | 2,226,015 | D | ↗ |
| 2025-05-01 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 298,886 | 1.34 | 400.5K | 3,104,139 | I | ↗ |
| 2025-04-30 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 437,881 | 1.41 | 617.4K | 3,403,025 | I | ↗ |
| 2025-04-29 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 250,000 | 1.41 | 352.5K | 3,840,906 | I | ↗ |
| 2025-04-28 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 215,283 | 1.56 | 335.8K | 4,090,906 | I | ↗ |
| 2025-04-25 | PERCEPTIVE ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 1,054,669 | 1.95 | 2.06M | 4,306,189 | I | ↗ |
| 2025-04-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 558 | 1.81 | 1.0K | 36,507 | D | ↗ |
| 2025-04-09 | Mirza Mansoor Raza | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-01 | Miller Mary | Officer | A-Award | A | Stock Option (Right to Buy) | 15,616 | 1.68 | 26.2K | 15,616 | D | ↗ |
| 2025-04-01 | Levy Adam D. | Officer | — | — | Common Stock | 0 | 0.00 | — | 13,315 | D | ↗ |
| 2025-03-01 | Peterson Katharine | Officer | A-Award | A | Stock Option (Right to Buy) | 31,900 | 5.31 | 169.4K | 31,900 | D | ↗ |
| 2025-03-01 | Miller Mary | Officer | A-Award | A | Stock Option (Right to Buy) | 93,693 | 5.31 | 497.5K | 93,693 | D | ↗ |
| 2025-03-01 | Holm-Jorgensen Rasmus | Officer | A-Award | A | Stock Option (Right to Buy) | 109,309 | 5.31 | 580.4K | 109,309 | D | ↗ |
| 2025-03-01 | Gamelin Erick | Officer | A-Award | A | Stock Option (Right to Buy) | 78,078 | 5.31 | 414.6K | 78,078 | D | ↗ |
| 2025-03-01 | Devroe Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 140,540 | 5.31 | 746.3K | 140,540 | D | ↗ |
| 2025-03-01 | Cuillerot Jean-Marie | Officer | A-Award | A | Stock Option (Right to Buy) | 78,078 | 5.31 | 414.6K | 78,078 | D | ↗ |
| 2025-03-01 | Blume-Jensen Peter | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 390,390 | 5.31 | 2.07M | 390,390 | D | ↗ |
| 2025-02-21 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 19,904 | 5.54 | 110.3K | 2,285,781 | D | ↗ |
| 2025-02-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 116 | 5.42 | 628.72 | 4,419 | D | ↗ |
| 2025-02-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 217 | 5.42 | 1.2K | 37,065 | D | ↗ |
| 2025-02-14 | Holm-Jorgensen Rasmus | Officer | F-InKind | D | Common Stock | 434 | 5.42 | 2.4K | 26,088 | D | ↗ |
| 2025-02-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 469 | 5.42 | 2.5K | 16,492 | D | ↗ |
| 2025-02-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 724 | 5.42 | 3.9K | 67,147 | D | ↗ |
| 2025-02-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 579 | 5.42 | 3.1K | 316,177 | I | ↗ |
| 2025-01-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 659 | 5.78 | 3.8K | 37,282 | D | ↗ |
| 2024-11-21 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 19,910 | 6.44 | 128.2K | 2,342,837 | D | ↗ |
| 2024-11-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 99 | 7.92 | 784.08 | 4,535 | D | ↗ |
| 2024-11-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 184 | 7.92 | 1.5K | 37,941 | D | ↗ |
| 2024-11-14 | Holm-Jorgensen Rasmus | Officer | F-InKind | D | Common Stock | 368 | 7.92 | 2.9K | 26,522 | D | ↗ |
| 2024-11-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 402 | 7.92 | 3.2K | 16,961 | D | ↗ |
| 2024-11-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 613 | 7.92 | 4.9K | 67,871 | D | ↗ |
| 2024-11-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 490 | 7.92 | 3.9K | 316,756 | I | ↗ |
| 2024-10-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 558 | 7.87 | 4.4K | 38,125 | D | ↗ |
| 2024-10-01 | Miller Mary | Officer | F-InKind | D | Common Stock | 284 | 6.98 | 2.0K | 38,683 | D | ↗ |
| 2024-08-21 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 79,616 | 9.19 | 731.7K | 2,422,513 | — | ↗ |
| 2024-08-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 99 | 7.02 | 694.98 | 4,634 | — | ↗ |
| 2024-08-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 184 | 7.02 | 1.3K | 38,967 | — | ↗ |
| 2024-08-14 | Masson Kristina | Director / Officer | F-InKind | D | Common Stock | 490 | 7.02 | 3.4K | 317,246 | — | ↗ |
| 2024-08-14 | Holm-Jorgensen Rasmus | Officer | F-InKind | D | Common Stock | 368 | 7.02 | 2.6K | 26,890 | — | ↗ |
| 2024-08-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 402 | 7.02 | 2.8K | 17,363 | — | ↗ |
| 2024-08-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 613 | 7.02 | 4.3K | 68,484 | — | ↗ |
| 2024-08-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 59,765 | 7.02 | 419.6K | 2,502,129 | — | ↗ |
| 2024-07-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 558 | 7.69 | 4.3K | 39,151 | — | ↗ |
| 2024-06-20 | TOMSICEK MICHAEL JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 6.52 | 132.2K | 20,275 | — | ↗ |
| 2024-06-20 | Shacham Sharon | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 6.52 | 132.2K | 20,275 | — | ↗ |
| 2024-06-20 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 20,275 | 6.52 | 132.2K | 20,275 | — | ↗ |
| 2024-06-20 | DiRocco Derek | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 6.52 | 132.2K | 20,275 | — | ↗ |
| 2024-06-20 | BAUM CHARLES M | Director | A-Award | A | Stock Option (Right to Buy) | 20,275 | 6.52 | 132.2K | 20,275 | — | ↗ |
| 2024-05-17 | Devroe Eric | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 1.04 | 10.4K | 86,615 | — | ↗ |
| 2024-05-14 | Peterson Katharine | Officer | F-InKind | D | Common Stock | 99 | 8.36 | 827.64 | 4,733 | — | ↗ |
| 2024-05-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 184 | 8.36 | 1.5K | 39,709 | — | ↗ |
| 2024-05-14 | Masson Kristina | Director / Officer | F-InKind | D | Common Stock | 490 | 8.36 | 4.1K | 317,736 | — | ↗ |
| 2024-05-14 | Holm-Jorgensen Rasmus | Officer | F-InKind | D | Common Stock | 368 | 8.36 | 3.1K | 27,258 | — | ↗ |
| 2024-05-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 402 | 8.36 | 3.4K | 17,765 | — | ↗ |
| 2024-05-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 613 | 8.36 | 5.1K | 59,097 | — | ↗ |
| 2024-05-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 54,918 | 8.36 | 459.1K | 2,561,894 | — | ↗ |
| 2024-05-13 | Peterson Katharine | Officer | — | D | Stock Option (Right to Buy) | 17,700 | 5.70 | 100.9K | 0 | — | ↗ |
| 2024-04-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 558 | 10.34 | 5.8K | 39,893 | — | ↗ |
| 2024-04-11 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Common Stock | 3,530,000 | 8.50 | 30.01M | 7,914,206 | — | ↗ |
| 2024-04-11 | PERCEPTIVE ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 2,353,000 | 8.50 | 20.00M | 5,360,858 | — | ↗ |
| 2024-03-04 | Palani Santhosh | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-01 | Miller Mary | Officer | A-Award | A | Stock Option (Right to Buy) | 67,567 | 5.70 | 385.1K | 67,567 | D | ↗ |
| 2024-03-01 | Holm-Jorgensen Rasmus | Officer | A-Award | A | Stock Option (Right to Buy) | 90,090 | 5.70 | 513.5K | 90,090 | D | ↗ |
| 2024-03-01 | Gamelin Erick | Officer | A-Award | A | Stock Option (Right to Buy) | 45,045 | 5.70 | 256.8K | 45,045 | D | ↗ |
| 2024-03-01 | Devroe Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 90,090 | 5.70 | 513.5K | 90,090 | D | ↗ |
| 2024-03-01 | Blume-Jensen Peter | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 90,090 | 5.70 | 513.5K | 90,090 | I | ↗ |
| 2024-02-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 217 | 3.40 | 737.80 | 40,451 | — | ↗ |
| 2024-02-14 | Masson Kristina | Director / Officer | F-InKind | D | Common Stock | 579 | 3.40 | 2.0K | 318,226 | — | ↗ |
| 2024-02-14 | Holm-Jorgensen Rasmus | Officer | F-InKind | D | Common Stock | 434 | 3.40 | 1.5K | 27,626 | — | ↗ |
| 2024-02-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 468 | 3.40 | 1.6K | 18,167 | — | ↗ |
| 2024-02-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 723 | 3.40 | 2.5K | 59,710 | — | ↗ |
| 2024-02-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 41,861 | 3.40 | 142.3K | 2,616,812 | — | ↗ |
| 2024-02-08 | Magovcevic-Liebisch Ivana | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 3.54 | 115.1K | 32,500 | — | ↗ |
| 2024-01-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 652 | 4.35 | 2.8K | 40,668 | — | ↗ |
| 2024-01-11 | Cuillerot Jean-Marie | Officer | A-Award | A | Stock Option (Right to Buy) | 99,300 | 4.82 | 478.6K | 99,300 | — | ↗ |
| 2024-01-02 | Cuillerot Jean-Marie | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-14 | Miller Mary | Officer | F-InKind | D | Common Stock | 735 | 5.08 | 3.7K | 41,320 | — | ↗ |
| 2023-11-14 | Masson Kristina | Director / Officer | F-InKind | D | Common Stock | 1,900 | 5.08 | 9.7K | 318,805 | — | ↗ |
| 2023-11-14 | Holm-Jorgensen Rasmus | Officer | F-InKind | D | Common Stock | 1,470 | 5.08 | 7.5K | 28,060 | — | ↗ |
| 2023-11-14 | Gamelin Erick | Officer | F-InKind | D | Common Stock | 1,395 | 5.08 | 7.1K | 18,635 | — | ↗ |
| 2023-11-14 | Devroe Eric | Officer | F-InKind | D | Common Stock | 2,450 | 5.08 | 12.4K | 60,433 | — | ↗ |
| 2023-11-14 | Blume-Jensen Peter | Director / Officer | F-InKind | D | Common Stock | 239,023 | 5.08 | 1.21M | 2,658,673 | — | ↗ |
| 2023-10-17 | Miller Mary | Officer | F-InKind | D | Common Stock | 2,232 | 5.48 | 12.2K | 42,055 | — | ↗ |
| 2023-09-26 | Miller Mary | Officer | — | D | Stock Option (Right to Buy) | 91,241 | 12.50 | 1.14M | 0 | — | ↗ |
| 2023-08-21 | Blume-Jensen Peter | Director / Officer | A-Award | A | Common Stock | 493,994 | 0.00 | — | 2,897,696 | — | ↗ |
| 2023-06-26 | Chione Ltd | 10% Owner | S-Sale | D | Common Stock | 16 | 12.93 | 206.88 | 3,848,632 | — | ↗ |
| 2023-06-22 | BAUM CHARLES M | Director | A-Award | A | Stock Option (Right to Buy) | 32,500 | 12.88 | 418.6K | 32,500 | — | ↗ |
| 2023-06-16 | Holm-Jorgensen Rasmus | Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,500 | 3.63 | 34.5K | 183,119 | — | ↗ |
| 2023-06-15 | Chione Ltd | 10% Owner | S-Sale | D | Common Stock | 2,056 | 12.14 | 25.0K | 3,848,648 | — | ↗ |
| 2023-06-14 | Chione Ltd | 10% Owner | S-Sale | D | Common Stock | 893 | 12.13 | 10.8K | 3,850,704 | — | ↗ |
| 2023-06-13 | Chione Ltd | 10% Owner | S-Sale | D | Common Stock | 3,000 | 12.30 | 36.9K | 3,851,597 | — | ↗ |
| 2023-06-12 | Chione Ltd | 10% Owner | S-Sale | D | Common Stock | 2,000 | 12.34 | 24.7K | 3,854,597 | — | ↗ |
| 2023-06-05 | Devroe Eric | Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,225 | 1.04 | 9.6K | 96,615 | — | ↗ |
| 2023-05-31 | Blume-Jensen Peter | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 33,605 | 3.88 | 130.4K | 90,855 | — | ↗ |
| 2022-11-17 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | C-Conversion | D | Series B Preferred Stock | 2,190,131 | 0.00 | — | 0 | — | ↗ |
| 2022-11-17 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | C-Conversion | A | Common Stock | 994,706 | 0.00 | — | 994,706 | — | ↗ |
| 2022-11-17 | PERCEPTIVE ADVISORS LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,007,858 | — | ↗ |
| 2022-11-17 | Chione Ltd | 10% Owner | C-Conversion | A | Common Stock | 10,657 | 5.62 | 59.9K | 3,856,597 | — | ↗ |
| 2022-11-14 | TOMSICEK MICHAEL JOHN | Director | A-Award | A | Stock Option (Right to Buy) | 35,235 | 12.50 | 440.4K | 35,235 | — | ↗ |
| 2022-11-14 | Shacham Sharon | Director | A-Award | A | Stock Option (Right to Buy) | 35,235 | 12.50 | 440.4K | 35,235 | — | ↗ |
| 2022-11-14 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 35,235 | 12.50 | 440.4K | 35,235 | — | ↗ |
| 2022-11-14 | DiRocco Derek | Director | A-Award | A | Stock Option (Right to Buy) | 35,235 | 12.50 | 440.4K | 35,235 | — | ↗ |
| 2022-11-14 | Devroe Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 100,150 | 0.00 | — | 100,150 | — | ↗ |
| 2022-11-09 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | — | D | Series B Preferred Stock | 888,130 | 0.00 | — | 0 | — | ↗ |
| 2022-11-09 | TOMSICEK MICHAEL JOHN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-09 | Shacham Sharon | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-09 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | — | I | Series B Preferred Stock | 426,302 | 0.00 | — | 0 | — | ↗ |
| 2022-11-09 | DiRocco Derek | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-09 | Chione Ltd | 10% Owner | — | D | Series A-1 Preferred Stock | 3,445,940 | 5.62 | 19.37M | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
31.56M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Director | 709.9K | — | — | 1.59M | 410.4K | 6.0K | 2.72M | 58.57% | ↗ |
| 2 | 2025 | Kristina Masson, Ph.D, M.B.A. Executive Vice President, Business Operations, Director | 594.5K | — | — | 573.2K | 251.2K | 6.0K | 1.42M | 40.23% | ↗ |
| 3 | 2025 | Eric Devroe, Ph.D. Chief Operating Officer | 528.7K | — | — | 573.2K | 250.1K | 6.0K | 1.36M | 42.21% | ↗ |
| 4 | 2024 | Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Director | 655.1K | — | — | 931.8K | 413.4K | — | 2.00M | 46.58% | ↗ |
| 5 | 2024 | Kristina Masson, M.B.A., Ph.D. Executive Vice President, Business Operations, Director | 565.5K | — | — | 372.7K | 258.9K | — | 1.20M | 31.13% | ↗ |
| 6 | 2024 | Kristina Masson, Ph.D, M.B.A. Executive Vice President, Business Operations, Director | 565.5K | — | — | 372.7K | 258.9K | — | 1.20M | 31.13% | ↗ |
| 7 | 2024 | Eric Devroe, Ph.D. Chief Operating Officer | 510.5K | — | — | 372.7K | 263.6K | — | 1.15M | 32.50% | ↗ |
| 8 | 2023 | Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Director | 629.0K | — | 5.49M | 348.7K | — | — | 6.47M | 90.27% | ↗ |
| 9 | 2023 | Kristina Masson, M.B.A., Ph.D. Executive Vice President, Business Operations, Director | 521.4K | — | — | 218.4K | — | — | 739.8K | 29.52% | ↗ |
| 10 | 2023 | Mary-Alice Miller, J.D. Chief Legal Officer | 418.5K | — | 34.5K | 75.4K | 168.6K | — | 697.0K | 15.77% | ↗ |
| 11 | 2022 | Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Director | 535.9K | — | 18.73M | 1.95M | 469.7K | — | 21.69M | 95.36% | ↗ |
| 12 | 2022 | Eric Devroe, Ph.D. Chief Operating Officer | 386.8K | — | 417.3K | 1.15M | 228.0K | — | 2.18M | 71.80% | ↗ |
| 13 | 2022 | Rasmus Holm-Jorgensen Chief Financial Officer | 288.2K | — | 250.4K | 1.05M | 136.6K | — | 1.72M | 75.31% | ↗ |
| 14 | 2021 | Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer, President and Director | 430.0K | — | — | 111.8K | 215.0K | — | 756.8K | 14.77% | ↗ |
| 15 | 2021 | Eric Devroe, Ph.D. Chief Operating Officer | 300.0K | — | — | 87.9K | 75.0K | — | 462.9K | 19.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Blume-Jensen | Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer | 1M | — |
| Kristina Masson | Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director | 851.7K | female |
| Eric J. Devroe | Chief Operating Officer | 784.8K | — |
| Mary-Alice Miller | Chief Legal Officer & Corporate Secretary | 587.1K | female |
| Erick Gamelin | Chief Development Officer | 480.7K | male |
| Adam D. Levy | Chief Financial Officer & Principal Financial Officer | — | — |
| Thomas Nifong | Head of Clinical CDx Operations | — | — |
| Bruce Close | Vice President of Quality & Compliance | — | male |
| Jesper V. Olsen | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board | — | — |
| Joon Jung | Vice President & Head of Data Science | — | male |
| Katharine Peterson | Vice President of Finance & Accounting | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACRV
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
